[go: up one dir, main page]

BR9812634A - April - uma proteìna com efeitos de crescimento - Google Patents

April - uma proteìna com efeitos de crescimento

Info

Publication number
BR9812634A
BR9812634A BR9812634-2A BR9812634A BR9812634A BR 9812634 A BR9812634 A BR 9812634A BR 9812634 A BR9812634 A BR 9812634A BR 9812634 A BR9812634 A BR 9812634A
Authority
BR
Brazil
Prior art keywords
april
protein
growth effects
growth
effects
Prior art date
Application number
BR9812634-2A
Other languages
English (en)
Inventor
Jurg Tschopp
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9812634A publication Critical patent/BR9812634A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"APRIL - UMA PROTEìNA COM EFEITOS DE CRESCIMENTO"<D>. Esta invenção refere-se a APRIL, um novo membro da família de fatores de necrose de tumores (TNFs), a APRILs modificadas e a composições farmacêuticas que as compreendem.
BR9812634-2A 1997-09-12 1998-09-11 April - uma proteìna com efeitos de crescimento BR9812634A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
BR9812634A true BR9812634A (pt) 2000-08-22

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812634-2A BR9812634A (pt) 1997-09-12 1998-09-11 April - uma proteìna com efeitos de crescimento

Country Status (20)

Country Link
US (3) US20030138884A1 (pt)
EP (1) EP1027431A2 (pt)
JP (1) JP2001515712A (pt)
KR (1) KR100618492B1 (pt)
CN (1) CN1195849C (pt)
AU (1) AU759717B2 (pt)
BR (1) BR9812634A (pt)
CA (1) CA2303615A1 (pt)
CZ (1) CZ294615B6 (pt)
EA (1) EA005411B1 (pt)
EE (1) EE200000147A (pt)
HU (1) HUP0004611A3 (pt)
IL (1) IL134537A0 (pt)
IS (1) IS5378A (pt)
NO (1) NO20001242L (pt)
NZ (1) NZ503850A (pt)
PL (1) PL339463A1 (pt)
SK (1) SK3542000A3 (pt)
TR (1) TR200000669T2 (pt)
WO (1) WO1999012965A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
EP1019508A1 (en) * 1997-09-30 2000-07-19 PHARMACIA &amp; UPJOHN COMPANY Tnf-related death ligand
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
BR0007719A (pt) 1999-01-25 2001-11-13 Biogen Inc Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
GEP20053685B (en) * 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
DK1666052T3 (da) 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
AU2001261557B2 (en) * 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2431054A3 (en) * 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
NZ543174A (en) 2003-03-28 2008-09-26 Biogen Idec Inc Truncated BAFF receptors
JP2008505607A (ja) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
EP1836224A1 (en) 2004-12-23 2007-09-26 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
WO2007019575A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
CA2651791A1 (en) 2006-05-15 2007-11-22 Ares-Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
CA2919467C (en) 2009-03-02 2018-04-17 Jan Paul Medema Antibodies against a proliferating inducing ligand (april)
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
WO2011108937A1 (en) * 2010-03-05 2011-09-09 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
SMT202300287T1 (it) * 2013-09-23 2023-11-13 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
KR102173297B1 (ko) * 2013-11-19 2020-11-03 리제너론 파마슈티칼스 인코포레이티드 인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
MX2018006385A (es) 2015-11-25 2019-09-11 Visterra Inc Moleculas de anticuerpo contra april y usos de las mismas.
US11484027B2 (en) 2020-10-29 2022-11-01 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
WO2023019223A2 (en) 2021-08-11 2023-02-16 Akso Biopharmaceutical Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
ATE254135T1 (de) * 1996-03-14 2003-11-15 Human Genome Sciences Inc Humaner tumornekrosefaktor delta und epsilon
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
CA2303615A1 (en) 1999-03-18
IS5378A (is) 2000-02-18
NO20001242D0 (no) 2000-03-09
EA005411B1 (ru) 2005-02-24
CZ2000869A3 (cs) 2000-09-13
SK3542000A3 (en) 2000-08-14
KR20010023893A (ko) 2001-03-26
US20060084148A1 (en) 2006-04-20
EP1027431A2 (en) 2000-08-16
HUP0004611A2 (hu) 2001-04-28
IL134537A0 (en) 2001-04-30
US20030138884A1 (en) 2003-07-24
US20050112596A1 (en) 2005-05-26
CZ294615B6 (cs) 2005-02-16
KR100618492B1 (ko) 2006-08-31
TR200000669T2 (tr) 2000-08-21
CN1195849C (zh) 2005-04-06
WO1999012965A2 (en) 1999-03-18
NZ503850A (en) 2002-12-20
CN1270632A (zh) 2000-10-18
HUP0004611A3 (en) 2002-04-29
EE200000147A (et) 2001-02-15
PL339463A1 (en) 2000-12-18
AU759717B2 (en) 2003-04-17
EA200000310A1 (ru) 2000-10-30
WO1999012965A3 (en) 1999-06-03
NO20001242L (no) 2000-05-11
AU9316298A (en) 1999-03-29
JP2001515712A (ja) 2001-09-25

Similar Documents

Publication Publication Date Title
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
BR9812433A (pt) Kay- uma proteìna do sistema de imunização
BR9711046A (pt) Ligando relacionado a fator de necrose de tumor.
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
BR0014214A (pt) Imidazoquinolinas substituìdas com amida
IL151313A0 (en) Lipase containing pharmaceutical compositions
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
DK0767800T3 (da) Histidin- og homohistidinderivater som inhibitorer af protein farnesyltransferase
ATE413386T1 (de) Ppar-gamma modulatoren
BR9804437A (pt) Compostos para a osteoporose
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
BR0300709A (pt) Sal de perindopril e as composições farmacêuticas contendo o mesmo
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
MXPA02010458A (es) Peptido modulador del receptor de trombopoyetina.
BR9507437A (pt) Base livre de halofantrina e composições para o tratamento da malária
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
IT1270618B (it) Proteine ad attivita&#39; antitumorale
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
ID25478A (id) Agonis 5-ht1f
DK0977871T3 (da) Neurotrypsin

Legal Events

Date Code Title Description
PC Transfer

Free format text: APOTECH R&D S.A. (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements